Advanced Lung Cancers: What's on the Horizon?

Access Course


884791.jpg?interpolation=lanczos-none&resize=300:225Experts review the latest abstracts and developments in NSCLC, SCLC, mesothelioma, and brain metastases. 

This activity is intended for hematologists/oncologists and pulmonologists.

The goal of this activity is to improve knowledge and implementation of clinically relevant data in the area of lung cancer from recent conferences.




Approximate Time to Complete: 30 minutes


Credit Available: Nov. 20, 2017 - Nov. 20, 2018


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the emerging clinical trial data on the use of cancer immunotherapies alone or in combination in the management of advanced lung cancers
  • Have increased knowledge regarding the potential impact of recent clinical data on treatment strategies for patients with advanced lung cancers in the community oncology setting
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50